[HTML][HTML] Gastrointestinal, liver and biliary tract pathology: a histopathological and epidemiological perspective from Pakistan with a review of the literature
Z Ahmad, H Arshad, S Fatima, R Idrees… - Asian Pacific Journal …, 2013 - koreascience.kr
Aim: To present an epidemiological and histological perspective of diseases of the
gastrointestinal tract (including liver and biliary tract) at the Section of Histopathology …
gastrointestinal tract (including liver and biliary tract) at the Section of Histopathology …
Tonglian Decoction (通莲汤) arrests the cell cycle in S-phase by targeting the nuclear factor-kappa B signal pathway in esophageal carcinoma Eca109 cells
Y Jia, X Hu, J Li, S Andras, G Hegyi, B Han - Chinese journal of integrative …, 2016 - Springer
Objective To investigate the anti-tumor activity and molecular mechanism of Tonglian
Decoction (通莲汤, TLD) on esophageal carcinoma Eca109 cells. Methods Eca109 cells …
Decoction (通莲汤, TLD) on esophageal carcinoma Eca109 cells. Methods Eca109 cells …
食管癌同步放化疗与序贯放化疗的疗效分析
武静， 任筱璐， 李波， 陈飞 - 中国药物与临床, 2015 - cqvip.com
食管癌是我国常见的恶性肿瘤, 有着较高的淋巴转移率及较高的局部未控和复发率,
对患者的生活质量及生存期均可造成严重的影响. 我国是食管癌高发国家 …
对患者的生活质量及生存期均可造成严重的影响. 我国是食管癌高发国家 …
[PDF][PDF] The decreased expression of protease-activated receptor 4 in esophageal squamous carcinoma
S Lee, P Jiang, W Wang, W Feng, G Yu - Neoplasma, 2014 - scholar.archive.org
Protease-activated receptors (PARs) are a unique family of G-protein coupled receptors.
PAR4, a member of PARs family, was reported to be related to the development of cancers …
PAR4, a member of PARs family, was reported to be related to the development of cancers …
[HTML][HTML] Adaptation of a quality of life questionnaire for Iranian patients with esophageal cancer
M Forootan, M Tabatabaeefar… - Indian journal of …, 2014 - ncbi.nlm.nih.gov
Materials and Methods: This study was designed as cross-sectional study on 62 newly
confirmed EC in two referral hospital in Tehran, Iran. Reliability of the subscales was …
confirmed EC in two referral hospital in Tehran, Iran. Reliability of the subscales was …
Tonglian Decoction (通莲汤) Arrests the Cell Cycle in S-phase by Targeting the Nuclear Factor-Kappa B Signal Pathway in Esophageal Carcinoma Eca109 Cells
贾永森， 胡雪琴， 李继安， 韩炳生 - 中国结合医学杂志: 英文版, 2016 - cqvip.com
Objective: To investigate the anti-tumor activity and molecular mechanism of Tonglian
Decoction (通莲汤, TLD) on esophageal carcinoma Eca109 cells. Methods: Eca109 cells …
Decoction (通莲汤, TLD) on esophageal carcinoma Eca109 cells. Methods: Eca109 cells …
食管癌适形调强放射治疗同步化疗的临床疗效观察
阿衣， 古丽， 哈热， 阿合力， 巴尔， 夏古丽， 张瑾熔 - 新疆医科大学学报, 2015 - cqvip.com
目的探讨局部晚期非手术食管癌患者同步放化疗后的近期疗效, 生存率及毒副反应.
方法选择未行手术的局部晚期食管癌患者108 例, 将其分为同步放化疗组(n= 66 例) …
方法选择未行手术的局部晚期食管癌患者108 例, 将其分为同步放化疗组(n= 66 例) …
A comparison of oesophageal cancer between the public and private sectors in KwaZulu-Natal
A Lutakwa, E Loots, MT Smith, DL Clarke - South African Journal of …, 2019 - ajol.info
Background: The frequency of the occurrence and type of oesophageal cancer from
pathology laboratory data from the private and public sector has never been compared in …
pathology laboratory data from the private and public sector has never been compared in …
[PDF][PDF] Histopathological Examination of the Esophageal Growth Endoscopic Specimens
F MEMON, K MEMON, J MEMON, N SHAIKH… - Growth, 2017 - pjmhsonline.com
Study setting and duration: Study was conducted at pathology department of LUMHS, from
January 2013 to December 2017. Material and methods: Patients presented with …
January 2013 to December 2017. Material and methods: Patients presented with …
[PDF][PDF] Survival benefit of (neo-) adjuvant radiotherapy to patients with T
Y Song, X Sun, G Cao, H Zhu, Q Guo - Int J Clin Exp Med, 2016 - e-century.us
Background and Aims: This study is designed to analyze survival benefit of (neo-) adjuvant
radiotherapy to patients with T2-3N0M0 stage squamous cell esophagus carcinoma …
radiotherapy to patients with T2-3N0M0 stage squamous cell esophagus carcinoma …